Skip to main content

Drug Interactions between FluMist and interferon alfa-2b / ribavirin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ribavirin influenza virus vaccine, live

Applies to: interferon alfa-2b / ribavirin and FluMist (influenza virus vaccine, live)

ADJUST DOSING INTERVAL: Antiviral agents that are active against influenza A and/or B viruses may conceivably interfere with the immunogenicity of live influenza virus vaccine by inhibiting the replication of vaccine virus. However, the potential for interaction has not been evaluated.

MANAGEMENT: Live influenza virus vaccine should not be administered until at least 48 hours after the cessation of antiviral therapy. Antiviral agents should not be administered until two weeks after immunization with live influenza virus vaccine unless medically indicated. If antiviral agents and live influenza virus vaccine are administered concomitantly, revaccination should be considered when appropriate. The product labeling for zanamivir recommends waiting 24 hours after cessation of the drug before administration of live influenza virus vaccine.

References

  1. "Product Information. Flumadine (riMANTAdine)." Forest Pharmaceuticals (2022):
  2. "Product Information. Relenza (zanamivir)." Glaxo Wellcome PROD (2001):
  3. "Product Information. Tamiflu (oseltamivir)." Roche Laboratories PROD (2001):
  4. "Product Information. FluMist (influenza virus vaccine, live)." Medimmune Inc (2022):
  5. "Product Information. Influenza Virus Vaccine, H1N1, Live (influenza virus vaccine, H1N1, live)." Medimmune Inc (2022):
  6. "Product Information. Rapivab (peramivir)." BioCryst Pharmaceuticals Inc (2015):
  7. "Product Information. FluMist Quadrivalent (influenza virus vaccine, live)." AstraZeneca Pharma Inc (2015):
  8. "Product Information. Xofluza (baloxavir marboxil)." Genentech (2018):
  9. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB "Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 influenza season." MMWR Recomm Rep 67 (2018): 1-20
View all 9 references

Switch to consumer interaction data

Drug and food interactions

Moderate

ribavirin food

Applies to: interferon alfa-2b / ribavirin

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of ribavirin. Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by up to 70% compared to administration in the fasting state.

MANAGEMENT: To ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.

References

  1. "Product Information. Copegus (ribavirin)." Roche Laboratories (2003):
  2. "Product Information. Rebetol (ribavirin)." Schering-Plough Corporation (2004):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer